Why Applied Materials, Inc. (NASDAQ:AMAT), Ross Stores, Inc. (NASDAQ:ROST) And Merck & Co. Inc (NYSE:MRK) Shares Should Be Watched?

Why Applied Materials, Inc. (NASDAQ:AMAT), Ross Stores, Inc. (NASDAQ:ROST) And Merck & Co. Inc (NYSE:MRK) Shares Should Be Watched?

0
614

There are three companies shares that could be monitored for intraday trading on Friday. That included Applied Materials, Inc. (NASDAQ:AMAT), Ross Stores, Inc. (NASDAQ:ROST) and Merck & Co. Inc (NYSE:MRK).

  • Applied Materials, Inc. (NASDAQ:AMAT) reported earnings of 79 cents a share for the second quarter that came in above predictions of 76 cents a share. Similarly, its revenue of $3.55 billion, which jumped 44.9 percent from the previous year period, also topped estimates of $3.54 billion. Going forward, the company expects adjusted EPS between 79 and 87 cents on revenue of $3.6 – $3.75 billion for the third quarter. Analysts are looking for an EPS of 69 cents and revenue of $3.42 billion. Following this, the stock managed to gain in the extended hours of trading on Thursday.
  • Ross Stores, Inc. (NASDAQ:ROST) jumped 4.19 percent in after-hours trading on Thursday after the company reported stronger than expected results for the first quarter. The company revealed an EPS of 82 cents, which came in two cents more than the Street analysts’ predictions of 80 cents. Similarly, its revenue of $3.31 billion topped estimates of $3.27 billion. Moving ahead, the company looks to deliver an EPS of 73 – 76 cents and same store sales growth of 1 – 2 percent for the second quarter. Analysts are looking for an EPS of 78 cents. For the full year, Ross Stores expects an EPS of $3.07 – $3.17 while analysts see $3.18.
  • Merck & Co., Inc. (NYSE:MRK) revealed that the FDA has given its approval for two fresh indications for its KEYTRUDA, pembrolizumab, its anti-PD1 therapy, for some patients suffering locally advanced or metastatic urothelial carcinoma. This is termed as a kind of bladder cancer. The company indicated that this indication was approved in accelerated approval based on tumor response rate and at the response duration. The pharmaceutical firm disclosed that that there are at least 29 clinical studies that are ongoing evaluating the PD-1 inhibitor in bladder cancer besides the nearly 500 clinical studies on the whole. This included over 250 in combinations.